Despite multiple clinical trials investigating LAG-3, both its roles in HCC and the consequent relationship with its ligand fibrinogen-like protein 1 (FGL1) have yet to be clearly defined. This evidence concerns the gene LAG3 and hepatocellular carcinoma.